Journal Mobile Options
Table of Contents
Vol. 17, No. 2, 2009
Issue release date: May 2009
Section title: Invited Review
Neurosignals 2009;17:144–152

Biological Mechanism of Antidepressant Effect of Omega–3 Fatty Acids: How Does Fish Oil Act as a ‘Mind-Body Interface’?

Su K.-P.
Department of General Psychiatry and Mind-Body Interface Laboratory (MBI-Lab), China Medical University and Hospital, Taichung, Taiwan; Stress, Psychiatry and Immunology Laboratory (SPI-Lab), Institute of Psychiatry, King’s College London, London, UK
email Corresponding Author

Dr. Kuan-Pin Su

Department of Psychiatry

China Medical University Hospital

No. 2, Yuh-Der Road, Taichung 404 (Taiwan)

Tel. +886 4 2206 2121, ext. 1076, Fax +886 4 2236 1230, E-Mail


  1. The World Health Report: Mental Health: New Understanding, New Hope. Geneva, WHO, 2001.
  2. Berton O, Nestler EJ: New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006;7:137–151.
  3. Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J: An international study of the relation between somatic symptoms and depression. N Engl J Med 1999;341:1329–1335.
  4. Katon W, Sullivan MD: Depression and chronic medical illness. J Clin Psychiatry 1990;51(suppl):3–11.
    External Resources
  5. Skolnick P: Beyond monoamine-based therapies: clues to new approaches. J Clin Psychiatry 2002;63(suppl 2):19–23.
    External Resources
  6. Horrobin DF, Bennett CN: Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Prostaglandins Leukot Essent Fatty Acids 1999;60:217–234.
  7. Horrobin DF: Phospholipid metabolism and depression: the possible roles of phospholipase A2 and coenzyme A-independent transacylase. Hum Psychopharmacol 2001;16:45–52.
  8. Su KP, Shen WW, Huang SY: Effects of polyunsaturated fatty acids on psychiatric disorders. Am J Clin Nutr 2000;72:1241.
  9. Das UN: Essential fatty acids: biochemistry, physiology and pathology. Biotechnol J 2006;1:420–439.
  10. Torpy JM, Lynm C, Glass RM: JAMA patient page. Eating fish: health benefits and risks. JAMA 2006;296:1926.
  11. Connor WE: Importance of n-3 fatty acids in health and disease. Am J Clin Nutr 2000;71:171S–175S.
  12. Chalon S: Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids 2006;75:259–269.
  13. Su KP, Huang SY, Chiu CC, Shen WW: Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003;13:267–271.
  14. Farooqui AA, Ong WY, Horrocks LA: Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev 2006;58:591–620.
  15. Hibbeln JR, Nieminen LR, Blasbalg TL, Riggs JA, Lands WE: Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr 2006;83:1483S–1493S.
  16. Hibbeln JR: Fish consumption and major depression. Lancet 1998;351:1213.
  17. Peet M, Murphy B, Shay J, Horrobin D: Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 1998;43:315–319.
  18. Adams PB, Lawson S, Sanigorski A, Sinclair AJ: Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 1996;31(suppl):S157–S161.
  19. Edwards R, Peet M, Shay J, Horrobin D: Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 1998;48:149–155.
  20. Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H: Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20:4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord 1996;38:35–46.
  21. Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY: Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1999;85:275–291.
  22. Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, Keck PE Jr, Marangell LB, Richardson AJ, Lake J, Stoll AL: Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 2006;67:1954–1967.
  23. Lin PY, Su KP: A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007;68:1056–1061.
  24. Nemets B, Stahl Z, Belmaker RH: Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002;159:477–479.
  25. Peet M, Horrobin DF: A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002;59:913–919.
  26. Frangou S, Lewis M, McCrone P: Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 2006;188:46–50.
  27. Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH: Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry 2006;163:1098–1100.
  28. Appleton KM, Hayward RC, Gunnell D, Peters TJ, Rogers PJ, Kessler D, Ness AR: Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr 2006;84:1308–1316.
  29. Rogers PJ, Appleton KM, Kessler D, Peters TJ, Gunnell D, Hayward RC, Heatherley SV, Christian LM, McNaughton SA, Ness AR: No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr 2008;99:421–431.
  30. Richardson AJ: n-3 Fatty acids and mood: the devil is in the detail. Br J Nutr 2008;99:221–223.
  31. Osher Y, Bersudsky Y, Belmaker RH: Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J Clin Psychiatry 2005;66:726–729.
  32. Su KP, Huang SY, Chiu TH, Huang KC, Huang CL, Chang HC, Pariante CM: Omega-3 fatty acids for major depressive disorder during pregnancy. Results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69:644–651.
  33. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB: Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999;56:407–412.
  34. Su KP, Shen WW, Huang SY: Are omega-3 fatty acids beneficial in depression but not mania? Arch Gen Psychiatry 2000;57:716–717.
  35. Chiu CC, Huang SY, Chen CC, Su KP: Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. J Clin Psychiatry 2005;66:1613–1614.
  36. Keck PE Jr, Mintz J, McElroy SL, Freeman MP, Suppes T, Frye MA, Altshuler LL, Kupka R, Nolen WA, Leverich GS, Denicoff KD, Grunze H, Duan N, Post RM: Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 2006;60:1020–1022.
  37. Freeman MP, Hibbeln JR, Wisner KL, Watchman M, Gelenberg AJ: An open trial of Omega-3 fatty acids for depression in pregnancy. Acta Neuropsychiatr 2006;18:21–24.
    External Resources
  38. Hamilton M: Frequency of symptoms in melancholia (depressive illness). Br J Psychiatry 1989;154:201–206.
  39. Tylee A, Gastpar M, Lepine JP, Mendlewicz J: DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol 1999;14:139–151.
  40. Kirmayer LJ, Robbins JM, Dworkind M, Yaffe MJ: Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993;150:734–741.
  41. Bair MJ, Robinson RL, Katon W, Kroenke K: Depression and pain comorbidity: a literature review. Arch Intern Med 2003;163:2433–2445.
  42. Kent S, Bluthe RM, Kelley KW, Dantzer R: Sickness behavior as a new target for drug development. Trends Pharmacol Sci 1992;13:24–28.
  43. Konsman JP, Parnet P, Dantzer R: Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 2002;25:154–159.
  44. Hart BL: Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 1988;12:123–137.
  45. Capuron L, Miller AH: Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004;56:819–824.
  46. Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000;157:867–876.
  47. Trask PC, Esper P, Riba M, Redman B: Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000;18:2316–2326.
  48. Raison CL, Demetrashvili M, Capuron L, Miller AH: Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005;19:105–123.
  49. Dantzer R: Somatization: a psychoneuroimmune perspective. Psychoneuroendocrinology 2005;30:947–952.
  50. Milton AS: Thermoregulatory actions of eicosanoids in the central nervous system with particular regard to the pathogenesis of fever. Ann N Y Acad Sci 1989;559:392–410.
  51. Mahony SM, Tisdale MJ: Role of prostaglandins in tumour necrosis factor induced weight loss. Br J Cancer 1989;60:51–55.
  52. Uehara A, Ishikawa Y, Okumura T, Okamura K, Sekiya C, Takasugi Y, Namiki M: Indomethacin blocks the anorexic action of interleukin-1. Eur J Pharmacol 1989;170:257–260.
  53. Lands WE: Biochemistry and physiology of n-3 fatty acids. FASEB J 1992;6:2530–2536.
  54. Song C, Li X, Leonard BE, Horrobin DF: Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats. J Lipid Res 2003;44:1984–1991.
  55. James MJ, Gibson RA, Cleland LG: Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000;71:343S–348S.
  56. Song C, Phillips AG, Leonard BE, Horrobin DF: Ethyl-eicosapentaenoic acid ingestion prevents corticosterone-mediated memory impairment induced by central administration of interleukin-1beta in rats. Mol Psychiatry 2004;9:630–638.
  57. Song C, Leonard BE, Horrobin DF: Dietary ethyl-eicosapentaenoic acid but not soybean oil reverses central interleukin-1-induced changes in behavior, corticosterone and immune response in rats. Stress 2004;7:43–54.
  58. Kempf K, Rose B, Herder C, Kleophas U, Martin S, Kolb H: Inflammation in metabolic syndrome and type 2 diabetes: Impact of dietary glucose. Ann N Y Acad Sci 2006;1084:30–48.
  59. Daryani A, Basu S, Becker W, Larsson A, Riserus U: Antioxidant intake, oxidative stress and inflammation among immigrant women from the Middle East living in Sweden: associations with cardiovascular risk factors. Nutr Metab Cardiovasc Dis 2006.
  60. Petersen AM, Pedersen BK: The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 2006;57 (suppl 10):43–51.
    External Resources
  61. Zuliani G, Ranzini M, Guerra G, Rossi L, Munari MR, Zurlo A, Volpato S, Atti AR, Ble A, Fellin R: Plasma cytokines profile in older subjects with late onset Alzheimer’s disease or vascular dementia. J Psychiatr Res 2007;41:686–693.
  62. Katon WJ: Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 2003;54:216–226.
  63. Delion S, Chalon S, Herault J, Guilloteau D, Besnard JC, Durand G: Chronic dietary alpha-linolenic acid deficiency alters dopaminergic and serotonergic neurotransmission in rats. J Nutr 1994;124:2466–2475.
  64. Chalon S, Vancassel S, Zimmer L, Guilloteau D, Durand G: Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. Lipids 2001;36:937–944.
  65. Berg KA, Maayani S, Clarke WP: 5-hydroxytryptamine2C receptor activation inhibits 5-hydroxytryptamine1B-like receptor function via arachidonic acid metabolism. Mol Pharmacol 1996;50:1017–1023.
  66. Farooqui AA, Hirashima Y, Horrocks LA: Brain phospholipases and their role in signal transduction. Adv Exp Med Biol 1992;318:11–25.
  67. Chalon S, Delion-Vancassel S, Belzung C, Guilloteau D, Leguisquet AM, Besnard JC, Durand G: Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J Nutr 1998;128:2512–2519.
  68. Delion S, Chalon S, Guilloteau D, Besnard JC, Durand G: alpha-Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J Neurochem 1996;66:1582–1591.
  69. Maes M, Meltzer HY: The serotonin hypothesis of major depression; in Bloom FE, Kupfer DJ (eds): Psychopharmacology, the Fourth Generation of Progress. New York, Raven Press, 1995, pp 933–941.
  70. Hibbeln JR, Linnoila M, Umhau JC, Rawlings R, George DT, Salem N Jr: Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics. Biol Psychiatry 1998;44:235–242.
  71. Nizzo MC, Tegos S, Gallamini A, Toffano G, Polleri A, Massarotti M: Brain cortex phospholipids liposomes effects on CSF HVA, 5-HIAA and on prolactin and somatotropin secretion in man. J Neural Transm 1978;43:93–102.
  72. Chiu CC, Huang SY, Su KP, Lu ML, Huang MC, Chen CC, Shen WW: Polyunsaturated fatty acid deficit in patients with bipolar mania. Eur Neuropsychopharmacol 2003;13:99–103.
  73. Linnoila M, Whorton AR, Rubinow DR, Cowdry RW, Ninan PT, Waters RN: CSF prostaglandin levels in depressed and schizophrenic patients. Arch Gen Psychiatry 1983;40:405–406.
  74. Ohishi K, Ueno R, Nishino S, Sakai T, Hayaishi O: Increased level of salivary prostaglandins in patients with major depression. Biol Psychiatry 1988;23:326–334.
  75. Noponen M, Sanfilipo M, Samanich K, Ryer H, Ko G, Angrist B, Wolkin A, Duncan E, Rotrosen J: Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol Psychiatry 1993;34:641–649.
  76. Chang MC, Contreras MA, Rosenberger TA, Rintala JJ, Bell JM, Rapoport SI: Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J Neurochem 2001;77:796–803.
  77. Ghelardoni S, Tomita YA, Bell JM, Rapoport SI, Bosetti F: Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain. Biol Psychiatry 2004;56:248–254.
  78. Das UN: Perinatal supplementation of long-chain polyunsaturated fatty acids, immune response and adult diseases. Med Sci Monit 2004;10:HY19–HY25.
  79. Farooqui AA, Ong WY, Horrocks LA: Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev 2006;58:591–620.
  80. Rapoport SI, Bosetti F: Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch Gen Psychiatry 2002;59:592–596.
  81. Rao JS, Lee HJ, Rapoport SI, Bazinet RP: Mode of action of mood stabilizers: is the arachidonic acid cascade a common target? Mol Psychiatry 2008;13:585–596.
  82. Das UN: Do polyunsaturated fatty acids behave like an endogenous ‘polypill’? Med Hypotheses 2008;70:430–434.
  83. Bazan NG: Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors. Trends Neurosci 2006;29:263–271.
  84. Lucas KK, Svensson CI, Hua XY, Yaksh TL, Dennis EA: Spinal phospholipase A2 in inflammatory hyperalgesia: role of group IVA cPLA2. Br J Pharmacol 2005;144:940–952.
  85. Uozumi N, Shimizu T: Roles for cytosolic phospholipase A2alpha as revealed by gene-targeted mice. Prostaglandins Other Lipid Mediat 2002;68–69:59–69.
  86. Pae CU, Yu HS, Kim JJ, Lee CU, Lee SJ, Lee KU, Jun TY, Paik IH, Serretti A, Lee C: BanI polymorphism of the cytosolic phospholipase A2 gene and mood disorders in the Korean population. Neuropsychobiology 2004;49:185–188.
  87. Su KP, Peng CY, Cheng JC, Pariante CM: Polymorphisms in cytosolic phospholipase A2 and cyclooxygenase 2 genes and risk of interferon-induced depression. Eur Neuropsychopharmacol 2007;17:S334–S335.
    External Resources
  88. Su KP: Mind-body interface: the role of n-3 fatty acids in psychoneuroimmunology, somatic presentation, and medical illness comorbidity of depression. Asia Pac J Clin Nutr 2008;17:147–153.
    External Resources
  89. Pascual RM, Carr EM, Seeds MC, Guo M, Panettieri RA Jr, Peters SP, Penn RB: Regulatory features of interleukin-1beta-mediated prostaglandin E2 synthesis in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2006;290:L501–L508.
  90. Morioka N, Takeda K, Kumagai K, Hanada T, Ikoma K, Hide I, Inoue A, Nakata Y: Interleukin-1beta-induced substance P release from rat cultured primary afferent neurons driven by two phospholipase A2 enzymes: secretory type IIA and cytosolic type IV. J Neurochem 2002;80:989–997.
  91. Hoozemans JJ, Veerhuis R, Janssen I, Rozemuller AJ, Eikelenboom P: Interleukin-1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer’s disease. Exp Gerontol 2001;36:559–570.
  92. Schmidlin F, Loeffler S, Bertrand C, Landry Y, Gies JP: PLA2 phosphorylation and cyclooxygenase-2 induction, through p38 MAP kinase pathway, is involved in the IL-1beta-induced bradykinin B2 receptor gene transcription. Naunyn Schmiedebergs Arch Pharmacol 2000;361:247–254.
  93. Hannigan GE, Williams BR: Signal transduction by interferon-alpha through arachidonic acid metabolism. Science 1991;251:204–207.
  94. Wu T, Levine SJ, Lawrence MG, Logun C, Angus CW, Shelhamer JH: Interferon-gamma induces the synthesis and activation of cytosolic phospholipase A2. J Clin Invest 1994;93:571–577.
  95. Wolbink GJ, Schalkwijk C, Baars JW, Wagstaff J, van den BH, Hack CE: Therapy with interleukin-2 induces the systemic release of phospholipase-A2. Cancer Immunol Immunother 1995;41:287–292.
  96. Visnjic D, Batinic D, Banfic H: Arachidonic acid mediates interferon-gamma-induced sphingomyelin hydrolysis and monocytic marker expression in HL-60 cell line. Blood 1997;89:81–91.
  97. Kambe T, Murakami M, Kudo I: Polyunsaturated fatty acids potentiate interleukin-1-stimulated arachidonic acid release by cells overexpressing type IIA secretory phospholipase A2. FEBS Lett 1999;453:81–84.
  98. Song C, Li X, Kang Z, Kadotomi Y: Omega- 3 fatty acid ethyl-eicosapentaenoate attenuates IL-1beta-induced changes in dopamine and metabolites in the shell of the nucleus accumbens involved with PLA2 activity and corticosterone secretion. Neuropsychopharmacology 2007;32:736–744.
  99. Tylee A, Gastpar M, Lepine JP, Mendlewicz J: DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol 1999;14:139–151.
  100. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH: Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002;26:643–652.
  101. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485–1492.
  102. Bair MJ, Robinson RL, Eckert GJ, Stang PE, Croghan TW, Kroenke K: Impact of pain on depression treatment response in primary care. Psychosom Med 2004;66:17–22.
  103. Yates WR, Mitchell J, John RA, Trivedi M, Wisniewski SR, Warden D, Bryan C, Fava M, Husain MM, Gaynes BN: Clinical features of depression in outpatients with and without co-occurring general medical conditions in STAR*D: confirmatory analysis. Prim Care Companion J Clin Psychiatry 2007;9:7–15.
    External Resources
  104. Corruble E, Guelfi JD: Pain complaints in depressed inpatients. Psychopathology 2000;33:307–309.